Commercial Credit Report for Adicet Bio Inc

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Adicet Bio Inc is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Adicet Bio Inc
131 Dartmouth Street, 3Rd Floor
Phone: (617) 482-2333p:617 482-2333	BOSTON, MA 02116 United States	Ticker: ACETACET

Business Summary

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
9/30/2024	12/31/2023	Yes	Yes	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Independent Chairman of the Board	Carl L.Gordon	59	1/1/2022	9/15/2020
President, Chief Executive Officer, Director	ChenSchor	51	1/1/2022
Chief Financial Officer	NickHarvey	63	9/15/2020	9/15/2020
7 additional Officers and Directors records available in full report.

Business Names

Business Name
ACET
Adicet Bio Israel Ltd.
Adicet Therapeutics, Inc.
Applied Immune Technologies, Ltd.

General Information

Number of Employees:	143	(As of 12/31/2023)
Outstanding Shares:	82,400,960	(As of 9/30/2024)
Shareholders:	16
Stock Exchange:	NASD
Federal Tax Id:	813305277
Fax Number:	(302) 655-5049